🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Brewer AB InBev partners with Tilray to tap cannabis drink market

Published 2018-12-19, 04:30 p/m
© Reuters.  Brewer AB InBev partners with Tilray to tap cannabis drink market
NOVN
-
STZ
-
MO
-
ABI
-
WEED
-
HEXO
-
CRON
-
TLRY
-

By Susan Taylor and Nichola Saminather

TORONTO, Dec 19 (Reuters) - Anheuser-Busch InBev ABI.BR , the world's largest brewer, and Canadian pot producer Tilray Inc TLRY.O are partnering in a $100-million joint venture to research cannabis-infused non-alcoholic drinks for the Canadian market, the companies said Wednesday.

The alliance, the latest in a string of deals by global alcohol and tobacco giants in Canada's cannabis sector, comes amid booming demand for cannabis and a long-term decline in alcohol consumption and smoking.

AB InBev's Labatt Breweries of Canada, which makes such brands as Labatt Blue and Budweiser, will work with Tilray's Canadian cannabis subsidiary, High Park Co, which develops and sells cannabis products in Canada, the companies said in a statement.

Canada, which became the world's first major country to fully legalize the recreational use of cannabis in October, is expected to approve cannabis-based products including beverages and edibles in October 2019.

“It's too early to know how big cannabinoid-based beverages will be but we think it's a massive opportunity and it's something we're interested in investing aggressively in," Tilray's Chief Executive Officer Brendan Kennedy told Reuters on Wednesday.

AB InBev and Tilray said they each plan to invest up to $50 million to research drinks with cannabidiol, or CBD, a component of cannabis that does not cause intoxication, and tetrahydrocannabinol, or THC, the substance that makes people high.

Discussions about commercialization are likely to follow, and Tilray's objective is to have beverages ready when they become legal in Canada, Kennedy said.

A gradual increase in legalized recreational use of cannabis for adults in U.S. states and in medical cannabis around the world has sparked investment and partnership deals for Canadian companies.

On Tuesday, Tilray said it will work with Sandoz AG, a unit of Swiss drug company Novartis AG NOVN.S , to develop and distribute medical marijuana world-wide. FWN1YN0HZ

Tilray is also exploring opportunities to make acquisitions in 2019, both within and outside the cannabis space, Kennedy said.

In the cannabis industry's largest investment, Corona beer maker Constellation Brands (NYSE:STZ) STZ.N added $4 billion to its $200 million investment in Canopy Growth WEED.TO in August to help fund the Canadian cannabis producer's global expansion. L4N1V63SO

In a more modest deal that same month, Molson Coors TAP.N , the No 2 beer maker in North America, struck a Canadian joint venture with marijuana producer Hexo Corp HEXO.TO to make cannabis drinks. L4N1US5HO

In the tobacco industry's first major foray into cannabis, Altria Group (NYSE:MO) MO.N said this month it would invest $1.8 billion in Cronos Group CRON.TO CRON.O for up to 55 percent of the Canadian cannabis producer. L4N1YC3UW

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.